NZ629621A - Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases - Google Patents
Alpha-1-microglobulin for use in the treatment of mitochondria-related diseasesInfo
- Publication number
- NZ629621A NZ629621A NZ629621A NZ62962113A NZ629621A NZ 629621 A NZ629621 A NZ 629621A NZ 629621 A NZ629621 A NZ 629621A NZ 62962113 A NZ62962113 A NZ 62962113A NZ 629621 A NZ629621 A NZ 629621A
- Authority
- NZ
- New Zealand
- Prior art keywords
- microglobulin
- mitochondria
- alpha
- treatment
- related diseases
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 102000003966 Alpha-1-microglobulin Human genes 0.000 title abstract 3
- 101800001761 Alpha-1-microglobulin Proteins 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 210000003470 mitochondria Anatomy 0.000 title abstract 2
- 230000004064 dysfunction Effects 0.000 abstract 2
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 abstract 1
- 206010003591 Ataxia Diseases 0.000 abstract 1
- 201000005943 Barth syndrome Diseases 0.000 abstract 1
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 abstract 1
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 abstract 1
- 208000035177 MELAS Diseases 0.000 abstract 1
- 208000035172 MERRF Diseases 0.000 abstract 1
- 208000022873 Ocular disease Diseases 0.000 abstract 1
- 101100240886 Rattus norvegicus Nptx2 gene Proteins 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 abstract 1
- 230000002438 mitochondrial effect Effects 0.000 abstract 1
- 208000019880 recessive mitochondrial ataxia syndrome Diseases 0.000 abstract 1
- 230000035806 respiratory chain Effects 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1722—Plasma globulins, lactoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201270538 | 2012-09-05 | ||
| DKPA201270557 | 2012-09-12 | ||
| PCT/EP2013/068270 WO2014037390A1 (en) | 2012-09-05 | 2013-09-04 | Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ629621A true NZ629621A (en) | 2015-09-25 |
Family
ID=49162118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ629621A NZ629621A (en) | 2012-09-05 | 2013-09-04 | Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10226507B2 (en:Method) |
| EP (1) | EP2900254B1 (en:Method) |
| JP (2) | JP2015533790A (en:Method) |
| KR (1) | KR20150047510A (en:Method) |
| CN (1) | CN104661673A (en:Method) |
| AU (1) | AU2013311714C1 (en:Method) |
| BR (1) | BR112015003957A2 (en:Method) |
| CA (1) | CA2881321A1 (en:Method) |
| DK (1) | DK2900254T3 (en:Method) |
| EA (1) | EA028963B1 (en:Method) |
| ES (1) | ES2599034T3 (en:Method) |
| HR (1) | HRP20161364T1 (en:Method) |
| HU (1) | HUE030559T2 (en:Method) |
| IN (1) | IN2015DN00515A (en:Method) |
| MX (1) | MX357656B (en:Method) |
| NZ (1) | NZ629621A (en:Method) |
| PL (1) | PL2900254T3 (en:Method) |
| PT (1) | PT2900254T (en:Method) |
| SG (1) | SG11201500669SA (en:Method) |
| WO (1) | WO2014037390A1 (en:Method) |
| ZA (1) | ZA201500547B (en:Method) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016204360A (ja) * | 2015-02-25 | 2016-12-08 | エー１エム ファーマ エービーＡ１Ｍ Ｐｈａｒｍａ ＡＢ | 放射性核種療法における腎臓の保護に用いるためのアルファ−１−ミクログロブリン |
| CA3014850A1 (en) * | 2016-02-25 | 2017-08-31 | A1M Pharma Ab | Alpha-1-microglobulin for use in the protection of kidneys in connection with use of contrast media |
| EA039776B1 (ru) * | 2016-03-18 | 2022-03-11 | Гард Терапьютикс Интернэшнл Айби | Новые белки, полученные из альфа-1-микроглобулина, и их применение |
| GB2566516A (en) | 2017-09-15 | 2019-03-20 | Univ Oxford Innovation Ltd | Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria |
| CN109867717A (zh) * | 2019-04-01 | 2019-06-11 | 山西瑞亚力生物技术有限公司 | 一种血浆中α1微球蛋白的提取方法 |
| CN110452980B (zh) * | 2019-09-23 | 2023-07-28 | 武汉儿童医院 | 一种线粒体脑肌病诊断试剂盒及应用 |
| WO2021062007A1 (en) * | 2019-09-25 | 2021-04-01 | Cytegen Corp. | Treatment of mitochondrial deficits and age-related diseases using blood products |
| CN115575646B (zh) * | 2022-11-21 | 2023-04-28 | 四川大学华西医院 | 一种代谢标志物组在制备预测癫痫发作的试剂盒中的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004292775A1 (en) * | 2003-11-26 | 2005-06-09 | Sanofi-Aventis Deutschland Gmbh | Tubular proteinuria as an indicator for elevated cardiovascular risk |
| PL2111555T3 (pl) * | 2007-02-12 | 2013-10-31 | A1M Pharma Ab | Diagnostyka stanu przedrzucawkowego |
| PL2300614T3 (pl) * | 2008-02-04 | 2016-04-29 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Sposoby i kompozycje do leczenia zaburzeń mitochondrialnych |
| WO2010006809A2 (en) | 2008-07-18 | 2010-01-21 | Akerstroem Bo | Medical use of the radical scavenger and antioxidant alpha-1-microglobulin |
-
2013
- 2013-09-04 HR HRP20161364TT patent/HRP20161364T1/hr unknown
- 2013-09-04 CA CA2881321A patent/CA2881321A1/en not_active Abandoned
- 2013-09-04 SG SG11201500669SA patent/SG11201500669SA/en unknown
- 2013-09-04 BR BR112015003957A patent/BR112015003957A2/pt not_active Application Discontinuation
- 2013-09-04 PT PT137599957T patent/PT2900254T/pt unknown
- 2013-09-04 US US14/423,260 patent/US10226507B2/en not_active Expired - Fee Related
- 2013-09-04 PL PL13759995T patent/PL2900254T3/pl unknown
- 2013-09-04 IN IN515DEN2015 patent/IN2015DN00515A/en unknown
- 2013-09-04 JP JP2015530375A patent/JP2015533790A/ja active Pending
- 2013-09-04 EA EA201590503A patent/EA028963B1/ru not_active IP Right Cessation
- 2013-09-04 ES ES13759995.7T patent/ES2599034T3/es active Active
- 2013-09-04 KR KR1020157005748A patent/KR20150047510A/ko not_active Ceased
- 2013-09-04 EP EP13759995.7A patent/EP2900254B1/en not_active Not-in-force
- 2013-09-04 MX MX2015002604A patent/MX357656B/es active IP Right Grant
- 2013-09-04 CN CN201380043567.0A patent/CN104661673A/zh active Pending
- 2013-09-04 DK DK13759995.7T patent/DK2900254T3/en active
- 2013-09-04 HU HUE13759995A patent/HUE030559T2/en unknown
- 2013-09-04 WO PCT/EP2013/068270 patent/WO2014037390A1/en active Application Filing
- 2013-09-04 AU AU2013311714A patent/AU2013311714C1/en not_active Ceased
- 2013-09-04 NZ NZ629621A patent/NZ629621A/en not_active IP Right Cessation
-
2015
- 2015-01-23 ZA ZA2015/00547A patent/ZA201500547B/en unknown
-
2018
- 2018-08-24 JP JP2018157394A patent/JP2018203756A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014037390A1 (en) | 2014-03-13 |
| ZA201500547B (en) | 2017-09-27 |
| SG11201500669SA (en) | 2015-02-27 |
| JP2015533790A (ja) | 2015-11-26 |
| EP2900254B1 (en) | 2016-08-03 |
| IN2015DN00515A (en:Method) | 2015-06-26 |
| PL2900254T3 (pl) | 2017-02-28 |
| ES2599034T3 (es) | 2017-01-31 |
| BR112015003957A2 (pt) | 2017-08-08 |
| AU2013311714C1 (en) | 2018-01-25 |
| PT2900254T (pt) | 2016-10-18 |
| CN104661673A (zh) | 2015-05-27 |
| MX2015002604A (es) | 2015-06-10 |
| EA028963B1 (ru) | 2018-01-31 |
| HRP20161364T1 (hr) | 2016-12-16 |
| DK2900254T3 (en) | 2016-08-29 |
| HK1210585A1 (en) | 2016-04-29 |
| EA201590503A1 (ru) | 2015-06-30 |
| KR20150047510A (ko) | 2015-05-04 |
| AU2013311714A1 (en) | 2015-03-12 |
| US20150258171A1 (en) | 2015-09-17 |
| EP2900254A1 (en) | 2015-08-05 |
| JP2018203756A (ja) | 2018-12-27 |
| HUE030559T2 (en) | 2017-05-29 |
| CA2881321A1 (en) | 2014-03-13 |
| AU2013311714B2 (en) | 2017-10-12 |
| US10226507B2 (en) | 2019-03-12 |
| MX357656B (es) | 2018-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ629621A (en) | Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases | |
| Mayama | Calcium channels and their blockers in intraocular pressure and glaucoma | |
| MX2016014634A (es) | Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. | |
| BR112016029675A2 (pt) | dispositivos dilatadores nasais | |
| UY33481A (es) | Compuesto para el tratamiento de trastornos y enfermedades del segmento posterior ocular | |
| BR112017024531A2 (pt) | lentes intraoculares ajustáveis por luz usando nanopartículas de conversão ascendente e luz do infravermelho próximo (nir) | |
| PH12019501902A1 (en) | Ocular formulations for drug-delivery to the posterior segment of the eye | |
| AR088165A1 (es) | Proteinas de funcion dual para tratar trastornos metabolicos | |
| MY171920A (en) | Prevention and treatment of ocular conditions | |
| CY1120642T1 (el) | Φαρμακευτικη συνθεση της ιβουπροφαιμνης και της τραμαδολης για οφθαλμολογικη χρηση | |
| MY171135A (en) | Antibodies specific for tgf-beta | |
| CO2017000346A2 (es) | Anticuerpos de unión a protofibrillas aβ | |
| PH12015501942A1 (en) | Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders | |
| MX390084B (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| ECSP11010956A (es) | Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos | |
| MX2025001445A (es) | Anticuerpos monoclonales anti-trkb y metodos de uso | |
| WO2015048188A3 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
| MA56220A (fr) | Formulations oculaires permettant l'administration de médicament et la protection du segment antérieur de l'oeil | |
| UY33153A (es) | Formulación tópica oftálmica de péptidos | |
| CR20130094A (es) | Agonistas de adenosina a1 para el tratamiento del glaucoma y la hipertensión ocular | |
| ECSP15009391A (es) | siARN Y SU USO EN LOS MÉTODOS Y COMPOSICIONES PARA EL TRATAMIENTO Y/O PREVENCIÓN DE ENFERMEDADES DE LOS OJOS | |
| IT1398378B1 (it) | Citicolina per il trattamento del glaucoma e dell'ipertensione oculare. | |
| MX381356B (es) | Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular. | |
| ZA202003944B (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye | |
| BR112017014379A2 (pt) | composição para o tratamento de infecções causadas pelo acaro demodex spp |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 SEP 2018 BY CPA GLOBAL(PATRAFEE) Effective date: 20170825 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 SEP 2019 BY CPA GLOBAL(PATRAFEE) AB Effective date: 20180808 |
|
| LAPS | Patent lapsed |